Lessons Learned From 2 Patients With Multidrug-Resistant HIV-1 Infection Successfully Treated With a Darunavir-Containing Antiretroviral Treatment Regimen
Free accessResearch articleFirst published online September, 2007
Lessons Learned From 2 Patients With Multidrug-Resistant HIV-1 Infection Successfully Treated With a Darunavir-Containing Antiretroviral Treatment Regimen
The authors describe 2 patients with life-threatening multidrug-resistant HIV-1 infection who responded very well to a treatment regimen containing darunavir and enfuvirtide. They discuss the availability of several new treatment options such as darunavir, etravirine, integrase, and CCR5 inhibitors for patients with multidrug-resistant viruses.
King NM, Prabu-Jeyabalan M., Nalivaika EA, Wigerinck P., de Béthune MP, Schiffer CAStructural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor. J Virol.2004;78:12012-12021.
2.
Pauwels R.Aspects of successful drug discovery and development. Antiviral Res.2006;71(2-3):77-89.
3.
Poveda E., Blanco F., Garcia-Gasco P., Alcolea A., Briz V., Soriano V.Successful rescue therapy with darunavir (TMC114) in HIVinfected patients who have failed several ritonavir-boosted protease inhibitors. AIDS. 2006;13;20(11):1558-1560.
4.
Lefebvre E., De Meyer S., De Paepe E., Hill A.TMC114/r provides greater efficacy benefits versus control protease inhibitor(s), regardless of the protease inhibitor or sensitivity to the protease inhibitor: POWER 1 and 2 trials. Eighth International conference on drug therapy in HIV infection, November 12-16, Glasgow , UK, abstract P29.
5.
Rockstroh J., Clumeck N., Spinosa-Guzman S., De Paepe E., Lefebvre E.TMC114/r has tolerability and efficacy benefits for treatment-experienced patients compared with control PIs: overview of the POWER trials. Eighth International conference on drug therapy in HIV infection, November 12-16, Glasgow, UK, abstract P28.
